Menu
No results found.
Weekly Share Price & Valuation Overview
Revenio Group Oyj
Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Probes that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used for measuring IOP on animal patients by general veterinary practitioners, veterinary ophthalmologists and other veterinary medical personnel. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.
- Healthy operating margin (≥15%) indicates efficient core operations.
- High gross margin (≥35%) suggests strong pricing power or cost control.
- Double-digit profit margin (≥10%) supports robust bottom-line economics.
- ROE ≥15% reflects strong returns on shareholder equity.
- ROA ≥7% shows efficient use of assets.
- Quick ratio ≥1.0 indicates obligations can be met without inventory.
- Market Cap Total equity value of the company (share price × shares outstanding).
- EUR 641.13M
- Enterprise Value Operating value: market cap + total debt − cash.
- EUR 643.79M
- Total Revenue (TTM) Sales over the last twelve months. May be estimated from revenue per share when inconsistent.
- EUR 107.22M
- Gross Profit (TTM) Revenue minus cost of goods sold over the last twelve months. Hidden for financial institutions or if redundant.
- EUR 76.54M
- EBITDA (TTM) Earnings before interest, taxes, depreciation and amortization (TTM). Hidden for financials or if implausible.
- EUR 30.20M
- Revenue per Share (TTM) Total revenue divided by shares outstanding (may be estimated).
- EUR 4.01
- EPS (TTM) Earnings per share over the last twelve months (may be estimated from net income ÷ shares).
- 0.68
- Dividend Yield Annual dividend ÷ share price. Reconciled using dividend per share when available.
- 1.65%
- Shares Outstanding
- 26.60M
- Float Shares
- 18.78M
- Implied Shares Outstanding
- 26.60M
- Operating Margin (TTM) Strong Operating income ÷ revenue over the last twelve months (reconciled when possible).
-
23.02%
- EBITDA Margin (TTM) Reconciled EBITDA ÷ revenue over the last twelve months (suppressed if EBITDA implausible/financials).
-
28.17%
- Gross Margin (TTM) Reconciled Strong Gross profit ÷ revenue over the last twelve months (reconciled when possible).
-
71.39%
- Profit Margin (TTM) Solid Net income ÷ revenue over the last twelve months (reconciled when possible).
-
16.88%
- ROA Strong Return on assets: net income ÷ total assets.
-
13.00%
- ROE Excellent Return on equity: net income ÷ shareholder equity.
-
17.91%
- Revenue Growth Year-over-year revenue growth.
-
3.90%
- Earnings Growth (YoY) Year-over-year earnings growth.
-
-25.20%
- Earnings Growth (QoQ) Quarter-over-quarter earnings growth.
-
-24.40%
- Quick Ratio Adequate Liquid current assets ÷ current liabilities (ex-inventory).
- 1.60
- Debt to Equity Total debt ÷ shareholder equity; leverage.
- 0.13
- Total Cash Cash and equivalents.
- EUR 14.00M
- Total Debt Short + long-term interest-bearing debt.
- EUR 14.00M
- Debt / EBITDA Leverage relative to operating earnings; lower is safer.
- 0.46
- Operating Cash Flow (TTM) Cash generated by core operations (pre-capex).
- EUR 24.07M
- Free Cash Flow (TTM) Cash after capex; funds buybacks, dividends, and debt paydown.
- EUR 12.92M
- OCF Margin (TTM) Operating cash flow ÷ revenue (TTM).
-
22.45%
- FCF Margin (TTM) Free cash flow ÷ revenue (TTM).
-
12.05%
- Cash Conversion (OpCF/EBITDA)
- 0.80
- Margins shown on a TTM basis. “Reconciled” = numerator ÷ TTM revenue for internal consistency.
- Cash Flow section is displayed only when figures are self-consistent (and hidden for financials).
Disclaimer: Information is compiled from publicly available sources and is subject to errors and omissions. It is provided as a guide only and does not constitute investment advice. Please do your own research.